| 書目名稱 | Immunogenicity of Biopharmaceuticals |
| 編輯 | Marco van de Weert,Eva Horn M?ller |
| 視頻video | http://file.papertrans.cn/463/462147/462147.mp4 |
| 概述 | First book to address the potential of an immune response to the biopharmaceutical product.Includes supplementary material: |
| 叢書名稱 | Biotechnology: Pharmaceutical Aspects |
| 圖書封面 |  |
| 描述 | .A particular issue for biopharmaceuticals that has not been addressed comprehensively in any book, is the potential of an immune response to the biopharmaceutical product. That is, the human body marks the drug as a foreign body, and develops antibodies against the drug. These antibodies may be relatively harmless, but may also cross-react with the endogenous compound, causing autoimmunogenicity. Recent adverse experiences in Europe with Janssen-Ortho’s blockbuster product Eprex has increased the attention towards potential immunogenicity of biopharmaceuticals, above all from the regulatory agencies...This book is intended to give a broad overview of the current state-of-the-art regarding the immune response to biopharmaceuticals. The chapters range from an overview of the immune system and factors that may trigger the immune system, via detection of antibodies and clinical implications, to various case examples and the regulatory view on immunogenicity. . |
| 出版日期 | Book 2008 |
| 關(guān)鍵詞 | Biosimilar; drug; interferon; pharmaceutical; reaction; research |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-0-387-75841-1 |
| isbn_softcover | 978-1-4419-2608-1 |
| isbn_ebook | 978-0-387-75841-1 |
| copyright | Springer-Verlag New York 2008 |
|Archiver|手機(jī)版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2026-1-29 05:05
發(fā)表于 2025-3-21 18:50:35
